India Pharma Outlook Team | Saturday, 06 June 2026
.jpeg "NPPA May Approve Price Hike for Key Cancer Drugs Amid Cost Surge")
India’s drug pricing regulator, the National Pharmaceutical Pricing Authority (NPPA), is considering a price hike for select platinum-based cancer drugs, following concerns over rising input costs and potential supply disruptions.
The proposed revision covers widely used oncology formulations such as carboplatin, cisplatin, and oxaliplatin—critical drugs used in treating cancers including head and neck, breast, and gastrointestinal malignancies.
The development follows a high-level meeting held on June 4 between the NPPA and leading pharmaceutical companies, including Pfizer, Fresenius, Zydus Lifesciences, and Hetero. Representatives from major cancer care institutions, including Tata Memorial Hospital, were also part of the discussions.
According to industry sources, manufacturers have sought a price increase of up to 50%, citing a sharp escalation in raw material costs particularly platinum, a key component in these drugs.
Over the past six months alone, input costs are estimated to have surged by more than 100%, significantly impacting production economics. In contrast, ceiling prices have seen only modest increases over the years. For instance, carboplatin’s price rose from Rs 49.38 in 2016 to about Rs 60.48 in April 2026, reflecting a relatively limited adjustment.
Experts warn that existing price controls, while essential for affordability, are now creating unintended supply-side challenges.
“There is a 22% increase in ceiling prices over the last decade, against a 225% rise in the cost of platinum,” said a source familiar with the matter, highlighting the widening gap between regulated prices and input costs.
Medical professionals have also raised concerns about the impact on patient care. Mohan Menon, medical oncologist at Lilavati Hospital, noted that the pricing constraints have made production financially unviable for several domestic manufacturers.
As a result, hospitals and oncologists are increasingly facing shortages, forcing them to delay treatment cycles, modify therapy protocols, or switch to alternative drugs—sometimes with limited clinical flexibility.
Also Read: India Tightens Drug Safety Norms, Mandates Pharmacovigilance Systems
The situation is being described as a “national urgency” by healthcare stakeholders, with calls for immediate regulatory intervention to stabilize supply chains and ensure continued patient access to essential cancer therapies.
The NPPA has asked manufacturers to submit detailed data on cost escalations over the past five years, including audited records, before taking a final call on price revisions.
If approved, the price hike could ease margin pressures on drugmakers and help restore production viability, particularly for essential but cost-sensitive oncology drugs.
At the same time, it raises a broader policy challenge—balancing affordability with sustainability in India’s price-controlled pharmaceutical market.
The NPPA’s potential move to revise prices of key cancer drugs reflects growing pressure within the pharma ecosystem. As raw material costs surge and supply tightens, regulatory recalibration may be critical to ensuring uninterrupted access to life-saving treatments.
.jpg)
